Opportunities to overcome underutilization of enhanced insulin delivery technologies in people with type 2 diabetes: a narrative review

ABSTRACT

Use of innovative technologies such as continuous glucose monitoring (CGM) and insulin delivery systems have been shown to be safe and effective in helping patients with diabetes achieve significantly improved glycemic outcomes compared to their previous therapies. However, these technologies are underutilized in many primary care practices. This narrative review discusses some of the clinical and economic benefits of tubeless insulin delivery devices and discusses how this technology can overcome the main obstacles inherent to use of conventional insulin delivery devices.

KEYWORDS:

• Type 2 diabetes
• insulin delivery
• disparities
• adherence

Declaration of financial/other relationships

D Kruger has served on advisory boards and/or speaker bureaus for, and her institution has received research support from Abbott Diabetes Care and Dexcom. D Isaacs has received speaker honoraria from Abbott Diabetes Care, Dexcom, Insulet, Medtronic, and Novo Nordisk. L Hughes has received honoraria from as a member of Abbott Diabetes Care Speaker’s Bureau and Embecta Advisory Board. E Miller has received consulting fees from Abbott, Astra Zeneca, Novo Nordisk Boehringer Ingelheim, Eli Lilly, Merck, Sanofi US, and has acted as a speaker for Abbott, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. TS Bailey has received research support from Abbott, Capillary Biomedical, Dexcom, Diasome, Eli Lilly, Kowa, Lexicon, Medtronic, Medtrum, Novo Nordisk, REMD, Sanofi, Senseonics, Viacyte, vTv Therapeutics and Zealand Pharma; consulting honoraria from Abbott, Lifescan, Novo Nordisk and Sanofi; and speaking honoraria from Medtronic and Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

A reviewer on this manuscript has received an honorarium from IPGM for their review work. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Acknowledgments

The authors wish to thank Christopher Parkin for his assistance in preparing this manuscript.

Author contributions

All authors contributed equally in the concept development, writing/revisions, and review of the final manuscript.

Additional information

Funding

Editorial assistance in writing this manuscript was funded by Embecta Corp. The sponsors had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript, and the authors received no compensation.